Skip to main content

Table 1 Selected laboratory results from in-house laboratory

From: The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report

Lab Results (Oslo) Unit [ref] \ Day # 1 2 4 6 13 20 27 37 45 63 73 149
Hemoglobin g/dL [11.7-15.3] 10.6 8.4 7.4 6.7 9.3 9.3 8.9 10.2   11.7 12.2 11.5
Reticulocytes 10E9/L 51 36 13 70 139 97 57 80     
Thrombocyte count 10E9/L [145-390] 20 < 10 32 72 312 339 405 512   371 406 260
LDH U/L [105-205] 2425 1060 1326 1399 411 334 261 205   159 173 164
Haptoglobin g/L [0.4-2.1] < 0.1 < 0.1 < 0.1 < 0.1 0.8   1.8   1.4   1.5 0.8
Leukocytes 10E9/L [3.5-10.0] 13.6 15 18.6 27.3 9 9.3 6.2 7.4 7.2 9.1 4.8 6.1
Ferritin μg/L [10-170] 1098 435 590 1152 714 567 493 410 264 69 72 33
CRP mg/L [<4] 418 160 50 132 49 80 9.8 7 1.6 25 1.6 0
Complement C1q mg/L [70-150]   63.2   104 154   152 164   165 145 128
Complement C3 g/L [0.70-2.00] 0.54 0.61   0.93 1.02 1.22 1.35 1.55   1.3 1.16 0.97
Complement C4 g/L [0.10-0.50] 0.21 0.04   0.19 0.26 0.27 0.28 0.35   0.31 0.27 0.19
C5b-9 ng/mL [<300] 816 353   275 111 135 180 204   138   
Classical pathway % [>40] 57 <1   13 4 42 2 2 <1 <1 <1 4
Lectin pathway % [>10] 6 <1   15 9 66 5 6 2 2 2 7
Alternative pathway % [>10] 36 <1   5 3 49 <1 1 <1 2 <1 3
sIL2r U/ml [ < 623] 7636 4942    4493   2965 1893 1170 1623 1399 868
Factor VIII activity % [50-150] 116    >150   >150   >150 >150   >150 137
VWf activity % [46-176] >200 >200     >200   >200 >200   164 139
VWf antigen % [52-178] >400 393     282   235 212   161 125
VWF collagen binding act. % [51-181] >200    163   >200   179 179   184 176
Creatinine μmol/L [45-90] 464 CRRT CRRT 429 pre IHD 361 pre IHD 584 398 248 191 157 145 132
  1. C5b-9 Soluble terminal complement complex, CRP C-reactive protein, CRRT continous renal replacement therapy, IHD intermittent hemodialysis, LDH Lactate dehydrogenase, sIL 2r Soluble interleukin 2 receptor, VWf von Willebrand factor
\